Carmen Peral

Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain

Federico Navarro, José Manuel Martínez Sesmero, Alejandro Balsa et al. · Clinical Rheumatology · 2020 · 21 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacology +15

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients

Darío Rubio-Rodríguez, Santiago Grau, Juan Carlos Pozo et al. · ClinicoEconomics and Outcomes Research · 2015 · 20 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

The cost‐effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

José Ramón Azanza Perea, Santiago Grau, Lourdes Vázquez et al. · Mycoses · 2020 · 16 citations · Full text

Pharmacy, Infectious Diseases, Pharmacoeconomics +17

Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain

Carmen Peral, Fernando Cordido, Vicente Gimeno‐Ballester et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2019 · 15 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain

Francesç Formiga, Pablo García‐Pavía, Francisco Javier Martín‐Sánchez et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2021 · 13 citations · Full text

Pharmacy, Cardiology, Pharmacoeconomics +17